Study S002003

A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00423501
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 306
Start: 2007-02
Primary completion: 2007-11
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Placebo; DRUG:taspoglutide
Results posted: FALSE

Registered primary outcomes

Absolute change from baseline in HbAlc [Week 8]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022337	Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Nauck MA, Diabetes care	2009	Randomized trial	PMID 19366970 DOI	cites ClinicalTrials.gov:NCT00423501; registry reference DERIVED:19366970